Skip to main content

Table 4 Clinical performance of DNA methylation and cytological analyses

From: Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites

  Diagnostic result (positive ascites from cancer patients)
Primary tumor Cellular or cell-free DNA methylation SEPT9 or SHOX2 Cytology Cellular or cell-free DNA methylation SEPT9 or SHOX2 or cytology
Digestive system 27/71 (38 %) 18/71 (25 %) 29/71 (41 %)
Stomach 2/6 (33 %) 2/6 (33 %) 3/6 (50 %)
Small intestine 0/2 (0 %) 0/2 (0 %) 0/2 (0 %)
Colona 2/8 (25 %) 0/8 (0 %) 2/8 (25 %)
Rectum 0/2 (0 %) 0/2 (0 %) 0/2 (0 %)
Anus, anal canal, and anorectuma 1/1 (100 %) 0/1 (0 %) 1/1 (100 %)
Liver and pancreasa 11/31 (35 %) 7/31 (23 %) 12/31 (39 %)
Gallbladder and bile ductsa 11/21 (52 %) 9/21 (43 %) 14/21 (67 %)
Respiratory system 1/5 (20 %) 0/5 (0 %) 1/5 (20 %)
Head and neck squamous cell carcinoma a 1/2 (50 %) 0/2 (0 %) 1/2 (50 %)
Lung and bronchusa 0/3 (0 %) 0/3 (0 %) 0/3 (0 %)
Pleural mesothelioma 1/1 (100 %) 1/1 (100 %) 1/1 (100 %)
Melanoma skin 0/1 (0 %) 0/1 (0 %) 0/1 (0 %)
Bones and joints 0/1 (0 %) 0/1 (0 %) 0/1 (0 %)
Breasta 1/6 (17 %) 1/6 (17 %) 1/6 (17 %)
Genital system 4/22 (18 %) 11/22 (50 %) 12/22 (55 %)
Uterine cervix and uterine corpus 0/2 (0 %) 0/2 (0 %) 0/2 (0 %)
Ovarya 5/18 (23 %) 11/18 (61 %) 12/18 (67 %)
Prostatea 0/2 (0 %) 0/2 (0 %) 0/2 (0 %)
Urinary System 2/6 (33 %) 2/6 (33 %) 3/6 (50 %)
Urinary bladder and renal pelvisa 1/4 (25 %) 1/4 (25 %) 1/4 (25 %)
Kidney 1/2 (50 %) 1/2 (50 %) 2/2 (100 %)
Brain and other nervous system 0/1 (0 %) 0/1 (0 %) 0/1 (0 %)
Lymphoma 4/17 (24 %) 0/17 (0 %) 4/17 (24 %)
Non-Hodgkin lymphomaa 4/11 (36 %) 0/11 (0 %) 4/11 (36 %)
Hodgkin lymphomaa 0/2 (0 %) 0/2 (0 %) 0/2 (0 %)
Myelomaa 0/4 (0 %) 0/4 (0 %) 0/4 (0 %)
Other and unspecified primary sites 1/3 (33 %) 2/3 (67 %) 2/3 (67 %)
  1. Tumor (organ)-specific performance of the developed assay and cytology. In a retrospective cohort study including ascites from 283 patients with suspected malignant disease and 134 patients with histological confirmed primary cancer. For more detailed information on DNA methylation results view Additional file 1. Patients indicated by asuffer from more than one primary tumor. For detailed information view Additional file 2